1.29% 0.0124

Ocean Biomedical Inc (OCEA)

Relative Volume:

ネットキャッシュフロー:

Ocean Biomedical Inc Stock (OCEA) Company Profile

Ocean Biomedical Inc

(646) 908-2658

515 MADISON AVE SUITE 8078, NEW YORK

OCEA's Discussions on Twitter

Ocean Biomedical Inc (OCEA) 最新ニュース

Ocean Biomedical Inc (OCEA) 財務データ

Ocean Biomedical Inc (OCEA)

Ocean Biomedical Inc Stock (OCEA) Company Profile

Ocean Biomedical Inc (OCEA) 最新ニュース

Dr. Chirinjeev Kathuria - Smart Business Dealmakers

Everything you need to know about Zenas BioPharma’s IPO - AlphaStreet

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms - ForexTV.com

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent - GlobeNewswire

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms - Morningstar

Ocean Biomedical, Inc. Announces Receipt of Notice from - GlobeNewswire

Ocean Biomedical Faces Nasdaq Compliance Challenges - TipRanks

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q - StockTitan

Ocean Biomedical (NASDAQ: OCEA) Research Summary - AlphaStreet

Ocean Biomedical Inc. (OCEA) Stock: Navigating a Year of Volatility - The InvestChronicle

U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.16% - MSN

Ocean Biomedical secures additional financing, issues equity - Investing.com

Financial Health Check: Examining Ocean Biomedical Inc. (OCEA)'s Key Ratios – DWinneX - The Dwinnex

Ocean Biomedical Inc. (OCEA) is a good investment, but the stock may be overvalued – US Post News - US Post News

Everything you need to know about OS Therapies’ upcoming IPO - AlphaStreet

3-Month SOFR (SQZ24) Quote - The Globe and Mail

Alumis looks to raise $300 million in IPO. Here’s what you need to know - AlphaStreet

Idiopathic Pulmonary Fibrosis Pipeline Analysis 2024: FDA Approval, Clinical Trials, Therapies, MOA, ROA by - EIN News

The Role of Horseshoe Crabs in the Biomedical Industry and Recent Trends Impacting Species Sustainability - Frontiers

Investing in Ocean Biomedical Inc. (OCEA) might be an excellent idea, but the stock is currently overvalued ... - US Post News

Best Penny Stocks for Today (Charts Updated Daily) • Benzinga - Benzinga

Biotech Stock Roundup: ZGNX's Acquisition News, REGN, BLUE's Updates & More - Yahoo Lifestyle UK

Biotech Stocks: The Top 5 To Watch As Shares Broadly Struggle - Investor's Business Daily

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace

TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail

Stocks Fall Before CPI Report and FOMC Meeting - The Globe and Mail

Stocks Settle Higher Ahead of the Tue/Wed FOMC Meeting - The Globe and Mail

Ocean Biomedical congratulates joint venture partner Virion TherapeuticsTipRanks.com - TipRanks

Tempus AI gears up for IPO. Here’s everything you need to know - AlphaStreet

Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive ... - GlobeNewswire

Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 - ForexTV.com

Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 - GlobeNewswire Inc.

Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure at EASL Congress - PR Newswire

Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a ... - PR Newswire

Stocks Climb on Positive Corporate News - The Globe and Mail

Ocean Biomedical receives notice of non-compliance from NasdaqTipRanks.com - TipRanks

Ocean Biomedical Faces Nasdaq Non-Compliance Notice and DelaysTipRanks.com - TipRanks

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form ... - GlobeNewswire

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q - GlobeNewswire Inc.

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q - Yahoo Finance

Stocks Mixed in TodayAfternoon Trade - Nasdaq

Ratio Review: Analyzing Ocean Biomedical Inc. (OCEA)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex

OCEA Stock Earnings: Ocean Biomedical Reported Results for Q3 2023 - InvestorPlace

Ocean Biomedical Inc.’s Shares Reel: 189.95% Quarterly Revenue Decline Amid 60.29M Market Cap - The InvestChronicle

Market Insight: Ocean Biomedical Inc. (OCEA)'s Notable Gain, Closing at 1.74 – DWinneX - The Dwinnex

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential ... - Markets Insider

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential ... - BioSpace

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease - ForexTV.com

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential - Daily Guardian Canada

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential ... - GlobeNewswire

Ocean Biomedical Inc (OCEA) 財務データ

収益

当期純利益

現金流量

EPS

OCEAに似た銘柄